Total Voting Rights

RNS Number : 4696R

The MedicX Fund Limited

25 October 2013

 



For immediate release                                                                                    

25 October 2013

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR JAPAN

MedicX Fund Limited

(the "Company")

Total Voting Rights, Transaction in Own Shares and Allotment of Shares to Directors and Investment Adviser

Total Voting Rights

Further to the Company's announcement on 23 October 2013 of the results of its Placing, Open Offer and Offer for Subscription (the "Issue"), 85 million new ordinary shares in the Company (the "Shares") were today admitted to the premium segment of the Official List of the UK Listing Authority and to trading on the main market for listed securities of the London Stock Exchange.  Of the 85 million Shares issued at 75p per Share (the "Issue Price"), 20 million were issued at the Issue Price to Canaccord Genuity Limited ("Canaccord"), the Company's broker.  The Company has today repurchased (in an on-market transaction) the 20 million Shares issued to Canaccord, into treasury, at the Issue Price, as provided for in the prospectus published by the Company on 25 September 2013 (the "Prospectus").

The total issued share capital of the Company consists of 361,445,780 Ordinary Shares, of which 21,539,066 are held in treasury. 

The figure of 339,906,714 may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Allotment of Shares to the Directors and to the Investment Adviser

A number of Shares have been issued to the Directors and MedicX Adviser Ltd, the Company's investment adviser (the "Investment Adviser") under applications made pursuant to the Issue. 

All of the Directors took up their entitlements under the Open Offer and, in addition, Ms Mason subscribed for a further 3,680 Shares under the Excess Application Facility.  Accordingly, the Directors (either personally or through trusts of which they are a beneficiary) hold the following Shares:

	Total Shares held	Percentage Holding
David Staples (Chairman)	74,434	0.022%
Christopher Bennett	10,573	0.003%
Shelagh Mason	24,910	0.007%
John Hearle	24,309	0.007%

The Investment Adviser took up its full entitlement under the Open Offer, being 254,430 Shares.  Accordingly, the Investment Adviser holds 1,808,814 Shares or 0.532% of the total voting rights.

Terms defined in the Prospectus shall have the same meanings in this announcement.

Further information on the Company can be found on the Company's website www.medicxfund.com.  

For further information please contact:

MedicX Fund                                                                [phone]

David Staples, Chairman

MedicX Group                                                              [phone]

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Canaccord Genuity Limited                                         [phone]

Andrew Zychowski /Lucy Lewis

Buchanan                                                                    [phone]

Charles Ryland /Sophie McNulty

Information on MedicX Fund Limited

MedicX Fund Limited is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 122 properties.

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Conduct Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 31 people operating across the UK.  

The Company's website address is www.medicxfund.com.  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

Important Information

This announcement is for information purposes only and does not constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities of the Company to any person in any jurisdiction and is not for release, publication or distribution in or into the United States, Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland. The New Ordinary Shares issued under the Open Offer, Offer for Subscription and the Placing have not been and will not be registered under the US Securities Act of 1933, as amended or under the applicable securities laws of Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland. Subject to certain exceptions, the New Ordinary Shares may not be offered sold or resold in the United States, Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland.

Canaccord Genuity Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as sponsor to MedicX Fund Limited and is acting for no-one else in connection with the Issue and the contents of this announcement, and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Canaccord Genuity Limited nor for providing advice in connection with the Issue and the contents of this announcement or any other matter referred to herein. Canaccord Genuity Limited is not responsible for the contents of this announcement. This does not exclude or limit any responsibilities which Canaccord Genuity Limited may have under the Financial Services and Markets Act 2000 (as amended) or the regulatory regime established thereunder.

 

END

 

 

MSCPGGAGUUPWGAA